Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
Our findings are consistent with GIPR research at large in that both enhancement and removal of GIPR signaling are metabolically beneficial. Notably, however, our findings suggest that future obesity therapies designed to modulate GIPR signaling, whether by agonism or antagonism, would be best targeted towards GABAergic neurons.
Authors
- Rhianna C. Laker (ORCID: https://orcid.org/0000-0002-0507-7838)
- Sarah Will
- Allison H. Kowalsky
- Jordan Wean
- Daniel J. Drucker (ORCID: https://orcid.org/0000-0001-6688-8127)
- Randy J. Seeley (ORCID: https://orcid.org/0000-0002-3721-5625)
- Christopher J. Rhodes (ORCID: https://orcid.org/0000-0002-7450-1110)
Institutions
- Mount Sinai Hospital (CA)
- University of Toronto (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- University of Michigan (US)
- Michigan Medicine (US)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1016/j.molmet.2024.102074
- Citations
- 18
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.44
Funders
- AstraZeneca
- National Institutes of Health